Login to Your Account



Pharma: Other News To Note


Thursday, May 24, 2012
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said the European Medicines Agency accepted the submission of a marketing authorization application for alogliptin, a selective dipeptidyl peptidase IV inhibitor in Type II diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription